Observations placeholder
Sutent
Identifier
020262
Type of Spiritual Experience
Number of hallucinations: 69
Background
A description of the experience
Sunitinib (marketed as Sutent and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications
On Jan, 10, 2017 28,301 people reported to have side effects when taking Sutent.
Among them, 69 people (0.24%) have Hallucination
Time on Sutent when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 44.00% | 48.00% | 0.00% | 8.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Sutent :
| Female | Male | |
| Hallucination | 32.86% | 67.14% |
Age of people who have Hallucination when taking Sutent :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7.32% | 12.20% | 80.49% |
On Jan, 25, 2016: 16,283 people reported to have side effects when taking Sutent. Among them, 2,774 people (17.04%) have Death.
Time on Sutent when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 36.34% | 39.44% | 15.21% | 7.04% | 1.69% | 0.28% | 0.00% |
Gender of people who have Death when taking Sutent :
| Female | Male | |
| Death | 32.41% | 67.59% |
Age of people who have Death when taking Sutent :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.07% | 0.87% | 4.24% | 10.77% | 23.28% | 60.77% |
Top conditions involved for these people :
- Metastatic renal cell carcinoma (913 people, 32.91%)
- Renal cell carcinoma (433 people, 15.61%)
- Gastrointestinal stromal tumour (302 people, 10.89%)
- Renal cancer (196 people, 7.07%)
- Renal cell carcinoma stage unspecified (65 people, 2.34%)